MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 10-31-2025
Thermo Fisher Scientific Retained Earnings 2011-2026 | TMO
Retained earnings — this is the portion of a company’s net profit that has not been distributed to shareholders as dividends but remains at the company’s disposal for future use. It is also referred to as retained income or accumulated earnings.Possible uses include
- reinvestment in development (R&D, equipment, marketing)
- debt repayment
- acquisition of other companies
- creation of reserves for the future
A high level of retained earnings indicates that the company is in a growth phase, accumulating capital and prioritizing reinvestment over dividend payouts. Conversely, low or negative retained earnings may suggest either a generous dividend policy, in which all profits are distributed to shareholders, or ongoing losses that reduce the overall financial result.
The presence of retained earnings does not indicate that the company has available cash — it is solely an accounting figure reflecting the accumulated portion of net profit remaining after dividends have been paid. Therefore, it is important for investors to analyze not only the amount of retained earnings, but also how effectively it is used to develop the business, reduce debt, or build financial stability.
Annual Retained Earnings Thermo Fisher Scientific
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 53.1 B | 47.4 B | 41.9 B | 35.4 B | 28.1 B | 22.1 B | 18.7 B | 15.9 B | 13.9 B | 12.1 B | 10.4 B | 8.75 B | 7.7 B | 6.72 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 53.1 B | 6.72 B | 23 B |
Quarterly Retained Earnings Thermo Fisher Scientific
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 57.4 B | 55.9 B | 54.4 B | 51.4 B | 49.9 B | 48.5 B | 45.9 B | 44.3 B | 43.1 B | 41.9 B | 40.5 B | - | 37.5 B | 35.4 B | 33.9 B | 32.1 B | 30.4 B | 28.1 B | 28.1 B | 28.1 B | 28.1 B | 22.1 B | 22.1 B | 22.1 B | 22.1 B | 18.7 B | 18.7 B | 18.7 B | 18.7 B | 15.9 B | 15.9 B | 15.9 B | 15.9 B | 13.9 B | 13.9 B | 13.9 B | 13.9 B | 12.1 B | 12.1 B | 12.1 B | 12.1 B | 10.4 B | 10.4 B | 10.4 B | 10.4 B | 8.75 B | 8.75 B | 8.75 B | 8.75 B | 7.7 B | 7.7 B | 7.7 B | 7.7 B | 6.72 B | 6.72 B | 6.72 B | 6.72 B |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 57.4 B | 6.72 B | 22.9 B |
Retained Earnings of other stocks in the Diagnostics research industry
| Issuer | Retained Earnings | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
-62.9 M | - | -6.23 % | $ 30.6 M |  Germany |
|
Akumin
AKU
|
-280 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
BioNano Genomics
BNGO
|
-693 M | $ 1.12 | -0.88 % | $ 1.42 M |  USA |
 |
Brainsway Ltd.
BWAY
|
-77.3 M | $ 24.41 | 1.2 % | $ 99.4 M |  Israel |
 |
Burning Rock Biotech Limited
BNR
|
-2.23 B | $ 27.63 | -4.06 % | $ 297 M |  China |
 |
Aspira Women's Health
AWH
|
-499 M | - | -6.19 % | $ 10.5 M | USA |
 |
Accelerate Diagnostics
AXDX
|
-607 M | - | -61.36 % | $ 2.46 M | USA |
 |
Celcuity
CELC
|
-272 M | $ 105.79 | 0.61 % | $ 4.17 B | USA |
 |
Biocept
BIOC
|
-298 M | - | -13.05 % | $ 7.29 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
-84 M | - | - | $ 562 M |  Britain |
 |
Check-Cap Ltd.
CHEK
|
-170 M | - | - | $ 9.42 M | Israel |
 |
Danaher Corporation
DHR
|
46.9 B | $ 209.19 | - | $ 149 B | USA |
 |
DarioHealth Corp.
DRIO
|
-349 M | $ 11.26 | - | $ 319 M | Israel |
 |
Chembio Diagnostics
CEMI
|
-154 M | - | 0.22 % | $ 16.8 M | USA |
 |
Enzo Biochem
ENZ
|
-294 M | - | -8.98 % | $ 14.8 K | USA |
 |
Fulgent Genetics
FLGT
|
590 M | $ 23.09 | 0.35 % | $ 698 M | USA |
 |
Co-Diagnostics
CODX
|
4.6 M | - | - | $ 79.8 M | USA |
 |
Global Cord Blood Corporation
CO
|
2.89 B | - | - | $ 399 M | China |
 |
Fluidigm Corporation
FLDM
|
-624 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
-150 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
-4.94 B | - | 0.12 % | $ 80.1 M | China |
 |
Quest Diagnostics Incorporated
DGX
|
9.36 B | $ 209.54 | - | $ 23.3 B | USA |
 |
Castle Biosciences
CSTL
|
-200 M | $ 29.94 | 3.46 % | $ 832 M | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
440 M | - | - | $ 10.7 B | USA |
 |
CareDx, Inc
CDNA
|
-678 M | $ 19.25 | 2.45 % | $ 1.03 B | USA |
 |
DermTech
DMTK
|
-424 M | - | -11.32 % | $ 2.94 M | USA |
 |
DexCom
DXCM
|
2.43 B | $ 73.09 | -0.23 % | $ 28.5 B | USA |
 |
Interpace Biosciences
IDXG
|
-235 M | $ 1.74 | -5.95 % | $ 7.63 M | USA |
 |
Exact Sciences Corporation
EXAS
|
-4.71 B | $ 103.45 | 0.06 % | $ 19.5 B | USA |
 |
Laboratory Corporation of America Holdings
LH
|
8.64 B | $ 287.13 | 0.64 % | $ 23.9 B | USA |
 |
Guardant Health
GH
|
-2.99 B | $ 95.4 | 1.04 % | $ 12 B | USA |
 |
QIAGEN N.V.
QGEN
|
2.45 B | - | - | $ 10.6 B |  Niderland |
 |
Charles River Laboratories International
CRL
|
1.39 B | $ 166.06 | - | $ 8.23 B | USA |
 |
Myriad Genetics
MYGN
|
-1.12 B | $ 4.43 | 1.14 % | $ 410 M | USA |
 |
Heska Corporation
HSKA
|
-169 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
-230 M | - | -20.0 % | $ 1.06 M | USA |
 |
ICON Public Limited Company
ICLR
|
2.72 B | $ 104.09 | -0.54 % | $ 8.59 B |  Irlanda |
 |
ENDRA Life Sciences
NDRA
|
-103 M | $ 3.86 | 2.93 % | $ 2.07 M | USA |
 |
IDEXX Laboratories
IDXX
|
6.39 B | $ 649.23 | 4.19 % | $ 52.2 B | USA |
 |
Illumina
ILMN
|
-1.24 B | $ 122.9 | 1.96 % | $ 19.5 B | USA |
 |
Natera
NTRA
|
-1.94 B | $ 209.53 | 0.09 % | $ 20.6 B | USA |
 |
IQVIA Holdings
IQV
|
7.42 B | $ 164.88 | - | $ 28.3 B | USA |
 |
Motus GI Holdings
MOTS
|
-154 M | - | -34.28 % | $ 263 K | Israel |
 |
Mettler-Toledo International
MTD
|
9.24 B | $ 1 379.66 | - | $ 28.4 B |  Schweiz |
|
Biodesix
BDSX
|
-462 M | $ 13.02 | 1.96 % | $ 1.69 B | USA |
 |
Quidel Corporation
QDEL
|
945 M | $ 21.93 | 3.49 % | $ 924 M | USA |
 |
Pacific Biosciences of California
PACB
|
-1.84 B | $ 1.66 | 5.06 % | $ 421 M | USA |
 |
Lantheus Holdings
LNTH
|
446 M | $ 73.61 | 0.26 % | $ 5.09 B | USA |
 |
Biomerica
BMRA
|
-53.2 M | $ 2.1 | - | $ 4.82 M | USA |